Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Chaumont-Gistoux – page 16

1 874 clinical trials in Chaumont-Gistoux, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Chaumont-Gistoux at a glance
1 874
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 874 trials in Chaumont-Gistoux

Open in trial search

Evaluation of NXT007 versus Emicizumab Prophylaxis in Patients with Hemophilia A

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Emicizumab
  • Sponsor:F. Hoffmann-La Roche AG

Myelofibrosis+1

Recruiting

Study of pelabresib (DAK539) plus ruxolitinib versus placebo plus ruxolitinib in adult patients with myelofibrosis who are JAK‑inhibitor‑naive

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Ruxolitinib
  • Sponsor:Novartis Pharma AG

Long‑Term Safety and Efficacy of RO7790121 in Adults with Moderate to Severe Rheumatoid Arthritis: Extension Study

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:RO7790121
  • Sponsor:F. Hoffmann-La Roche AG

Crohn's disease

Recruiting

A Phase 3b Study of Guselkumab Compared with Risankizumab in Adults with Moderately to Severely Active Crohn’s Disease

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Guselkumab
  • Sponsor:Janssen Cilag International

Asthma

Recruiting

Efficacy and safety of GB-0895 as adjunctive therapy in adults and adolescents with severe uncontrolled asthma (randomized, placebo‑controlled)

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:GB-0895
  • Sponsor:Generate Biomedicines Inc.

Phase 3 Randomized Double‑Blind Placebo‑Controlled Study of Intravenous sgt-003 in Ambulatory Male Patients with Duchenne Muscular Dystrophy

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:SGT-003
  • Sponsor:Solid Biosciences Inc.

Pumitamig Versus Durvalumab in Patients With Unresectable Stage III Non-Small Cell Lung Cancer Without Progression After Chemoradiation

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

EIK1001, Pembrolizumab, and Chemotherapy for Stage 4 Non-Small Cell Lung Cancer in Patients with Stage 4 Non-Small Cell Lung Cancer

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Eikon Therapeutics Inc.

Duchenne Muscular Dystrophy in Patients with Gene Mutations Amenable to Exon 44 Skipping Treated with Delpacibart Zotadirsen

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Delpacibart zotadirsen
  • Sponsor:Avidity Biosciences Inc.

INCA33890 With Standard Chemotherapy and Bevacizumab in First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Incyte Corp.

VMX-C001 in Patients Taking Factor Xa Inhibitors Who Need Urgent Surgery or an Invasive Procedure With High Bleeding Risk

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:VMX-C001
  • Sponsor:VarmX B.V.

Bisoprolol in Patients After Myocardial Infarction with Preserved Ejection Fraction During Cardiac Rehabilitation

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Bisoprolol
  • Sponsor:UZ Leuven

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Chaumont-Gistoux

What the registry says about research in the country

01 Gastroenterology Research

Innovative clinical trials focusing on proton pump inhibitor (PPI) de-prescribing strategies for patients with chronic usage patterns. This research evaluates different approaches to medication management for individuals with functional dyspepsia and reflux conditions.

  • PPI De-prescribing Methods
  • Gastrointestinal Health Management
  • Alternative Treatment Approaches

The study explores on-demand medication use and alternative therapeutic options, aiming to establish optimal treatment protocols for long-term digestive health management.

02 Digestive Health Studies

Research examining the effectiveness of different management strategies for heartburn and reflux symptoms. The trials evaluate various therapeutic approaches, including alginate formulations as alternative treatments.

  • Symptom Management
  • Treatment Optimization
  • Patient-Centered Care

These investigations aim to improve quality of life for patients while identifying more targeted and efficient treatment strategies.

03 Primary Care Innovation

Forward-thinking research in primary care settings focusing on medication optimization and patient-centered approaches to chronic condition management.

  • Medication Management
  • Evidence-Based Protocols
  • Clinical Practice Enhancement

This research aims to establish better guidelines for long-term medication management in primary care practices.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.